Höbarth K, Hallas A, Kramer G, Aulitzky W, Gomahr A, Steiner G, Marberger M
Department of Urology, University of Vienna, Austria.
Eur Urol. 1996;30(1):89-95. doi: 10.1159/000474151.
The usefulness of serum tissue polypeptide-specific antigen (TPS), a cytokeratin 18-associated marker, in renal cell carcinoma (RCC) was assessed in vitro and in vivo.
Indirect immunoperoxidase staining for TPS expression was performed on frozen sections of normal renal tissue and RCC specimens. By using a monoclonal TPS immunoradiometric assay, serum TPS concentrations were analyzed in 82 healthy controls, in 20 patients with locoregional RCC before and after surgery and in 18 patients with advanced disease following surgery receiving immunotherapy with interferon-gamma.
Using immunohistochemistry, TPS was found to be expressed by both normal and cancerous renal epithelial cells. The mean TPS concentrations in 82 healthy controls was 56 +/- 49 U/1 with a 95% percentile of 78.5 U/1. Out of 20 patients with locoregional RCC, 8 presented with elevated values (mean 168 +/- 82 U/1) above the cut-off level (78.5 U/1, sensitivity 40%) which dropped to normal within 2 weeks after surgery. During a follow-up period of 1 year, none of the patients presented with tumor recurrence and TPS concentrations remained low (mean 52 +/- 36 U/1). In 18 patients receiving interferon-gamma therapy, serum TPS concentrations were monitored over a period of 12 months. In 5/18 patients, baseline levels were within the normal range (mean 37 +/- 21 U/1); interestingly, these at the same time were the only responders to immunotherapy (n = 2) or at least showed stable disease (n = 3). Response to therapy was reflected by low serum TPS levels (mean 28 +/- 23 U/1) over the entire observation period. Thirteen patients suffered progressive disease during therapy, all of them exhibiting significantly elevated (p < 0.005) pretherapeutic TPS concentrations (mean 186 +/- 124 U/1) that remained equally elevated throughout therapy (mean 192 +/- 102 U/1), reflecting tumor progression.
TPS might have some clinical value as prognostic marker in RCC, possibly by reflecting the proliferative tendency of the tumor.
在体外和体内评估血清组织多肽特异性抗原(TPS,一种细胞角蛋白18相关标志物)在肾细胞癌(RCC)中的应用价值。
对正常肾组织和肾细胞癌标本的冰冻切片进行TPS表达的间接免疫过氧化物酶染色。使用单克隆TPS免疫放射分析方法,对82名健康对照者、20名局部肾细胞癌患者手术前后以及18名晚期疾病患者术后接受γ干扰素免疫治疗前后的血清TPS浓度进行分析。
通过免疫组织化学发现,正常和癌性肾上皮细胞均表达TPS。82名健康对照者的平均TPS浓度为56±49 U/1,95百分位数为78.5 U/1。20名局部肾细胞癌患者中,8名患者的值高于临界值(78.5 U/1,敏感性40%),平均为168±82 U/1,术后2周内降至正常。在1年的随访期内,所有患者均未出现肿瘤复发,TPS浓度保持较低水平(平均52±36 U/1)。对18名接受γ干扰素治疗的患者在12个月内监测血清TPS浓度。18名患者中有5名基线水平在正常范围内(平均37±21 U/1);有趣的是,这些患者同时是免疫治疗的唯一有效者(n = 2)或至少表现为病情稳定(n = 3)。整个观察期内血清TPS水平较低(平均28±23 U/1)反映了对治疗的反应。13名患者在治疗期间病情进展,所有患者治疗前TPS浓度显著升高(p < 0.005),平均为186±124 U/1,整个治疗过程中一直保持升高(平均192±102 U/1),反映了肿瘤进展。
TPS可能作为肾细胞癌的预后标志物具有一定临床价值,可能是通过反映肿瘤的增殖倾向。